Zymeworks Inc. announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer (CEO) of Zymeworks, effective on or before February 1, 2022. Mr. Galbraith will succeed Zymeworks co-founder Ali Tehrani, Ph.D., who has served as President and CEO since 2003. Dr. Tehrani will remain as an advisor to the Company to assist with the transition.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.88 USD | +5.84% |
|
+4.35% | -14.53% |
06-17 | Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy | MT |
06-17 | Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.53% | 633M | |
+16.61% | 122B | |
+17.75% | 112B | |
+18.69% | 25.91B | |
-24.11% | 19.33B | |
-17.80% | 16.17B | |
-18.47% | 15.6B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc. Announces Executive Changes